Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Chris Labaki, Toni K. Choueiri, Ziad Bakouny et al.|Journal of Clinical Oncology|2023Cited by 4
Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Kosuke Takemura, Daniel Yick Chin Heng, Frede Donskov et al.|Journal of Clinical Oncology|2023Cited by 4
Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo+Ipi): Results from the International mRCC Database Consortium (IMDC).Audreylie Lemelin, Daniel Yick Chin Heng, Kosuke Takemura et al.|Journal of Clinical Oncology|2023Cited by 3
Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).J. Connor Wells, Daniel Yick Chin Heng, Evan Ferrier et al.|Journal of Clinical Oncology|2024Cited by 2
Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.Renée Maria Saliby, Toni K. Choueiri, Wanling Xie et al.|Journal of Clinical Oncology|2024Cited by 1